Bioinorganic Chemistry and Applications

Copyright © 2014 Burcu Saygıdeğer Demir et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

1. W. Zhong, T. Yan, R. Lim, and L. W. Oberley, “Expression of superoxide dismutases, catalase, and glutathione peroxidase in glioma cells,” Free Radical Biology and Medicine, vol. 27, no. 11-12, pp. 1334–1345, 1999. View at Publisher · View at Google Scholar · View at Scopus
2. D. Deeb, X. Gao, H. Jiang et al., “Oleanane triterpenoid CDDO-Me inhibits growth and induces apoptosis in prostate cancer cells through a ROS-dependent mechanism,” Biochemical Pharmacology, vol. 79, no. 3, pp. 350–360, 2010. View at Publisher · View at Google Scholar · View at Scopus
3. X. Yang, L. Chen, Y. Liu et al., “Ruthenium methylimidazole complexes induced apoptosis in lung cancer A549 cells through intrinsic mitochondrial pathway,” Biochimie, vol. 94, no. 2, pp. 345–353, 2012. View at Publisher · View at Google Scholar · View at Scopus
4. V. Gandin, A. P. Fernandes, M. P. Rigobello et al., “Cancer cell death induced by phosphine gold(I) compounds targeting thioredoxin reductase,” Biochemical Pharmacology, vol. 79, no. 2, pp. 90–101, 2010. View at Publisher · View at Google Scholar · View at Scopus
5. S. Urig and K. Becker, “On the potential of thioredoxin reductase inhibitors for cancer therapy,” Seminars in Cancer Biology, vol. 16, no. 6, pp. 452–465, 2006. View at Publisher · View at Google Scholar · View at Scopus
6. O. Zava, S. M. Zakeeruddin, C. Danelon, H. Vogel, M. Grätzel, and P. J. Dyson, “A cytotoxic ruthenium tris(Bipyridyl) complex that accumulates at plasma membranes,” ChemBioChem, vol. 10, no. 11, pp. 1796–1800, 2009. View at Publisher · View at Google Scholar · View at Scopus
7. F. Linares, M. A. Galindo, S. Galli, M. A. Romero, J. A. R. Navarro, and E. Barea, “Tetranuclear coordination assemblies based on half-sandwich ruthenium(II) complexes: noncovalent binding to DNA and cytotoxicity,” Inorganic Chemistry, vol. 48, no. 15, pp. 7413–7420, 2009. View at Publisher · View at Google Scholar · View at Scopus
8. S. H. van Rijt, A. J. Hebden, T. Amaresekera et al., “Amide linkage isomerism as an activity switch for organometallic osmium and ruthenium anticancer complexes,” Journal of Medicinal Chemistry, vol. 52, no. 23, pp. 7753–7764, 2009. View at Publisher · View at Google Scholar · View at Scopus
9. X. Meng, M. L. Leyva, M. Jenny et al., “A ruthenium-containing organometallic compound reduces tumor growth through induction of the endoplasmic reticulum stress gene CHOP,” Cancer Research, vol. 69, no. 13, pp. 5458–5466, 2009. View at Publisher · View at Google Scholar · View at Scopus
10. E. Meggers, G. E. Atilla-Gokcumen, K. Gründler, C. Frias, and A. Prokop, “Inert ruthenium half-sandwich complexes with anticancer activity,” Dalton Transactions, no. 48, pp. 10882–10888, 2009. View at Publisher · View at Google Scholar · View at Scopus
11. N. Farrell, Y. Qu, U. Bierbach, M. Valsecchi, and E. Menta, Cis-Platin: Chemistry and Biochemistry of a Leading Anticancer Drug, Wiley, Weinheim, Germany, 1999.
12. C. K. Mirabelli, R. K. Johnson, C. M. Sung, L. Faucette, K. Muirhead, and S. T. Crooke, “Evaluation of the in vivo antitumor activity and in vitro cytotoxic properties of auranofin, a coordinated gold compound, in murine tumor models,” Cancer Research, vol. 45, no. 1, pp. 32–39, 1985. View at Google Scholar · View at Scopus
13. C. Santini, M. Pellei, G. Papini et al., “In vitro antitumour activity of water soluble Cu(I), Ag(I) and Au(I) complexes supported by hydrophilic alkyl phosphine ligands,” Journal of Inorganic Biochemistry, vol. 105, no. 2, pp. 232–240, 2011. View at Publisher · View at Google Scholar · View at Scopus
14. N. Manav, A. K. Mishra, and N. K. Kaushik, “Triphenyl phosphine adducts of platinum(IV) and palladium(II) dithiocarbamates complexes: a spectral and in vitro study,” Spectrochimica Acta—Part A: Molecular and Biomolecular Spectroscopy, vol. 60, no. 13, pp. 3087–3092, 2004. View at Publisher · View at Google Scholar · View at Scopus
15. C. Wetzel, P. C. Kunz, M. U. Kassack et al., “Gold(I) complexes of water-soluble diphos-type ligands: synthesis, anticancer activity, apoptosis and thioredoxin reductase inhibition,” Dalton Transactions, vol. 40, no. 36, pp. 9212–9220, 2011. View at Publisher · View at Google Scholar · View at Scopus
16. O. Rackham, S. J. Nichols, P. J. Leedman, S. J. Berners-Price, and A. Filipovska, “A gold(I) phosphine complex selectively induces apoptosis in breast cancer cells: implications for anticancer therapeutics targeted to mitochondria,” Biochemical Pharmacology, vol. 74, no. 7, pp. 992–1002, 2007. View at Publisher · View at Google Scholar · View at Scopus
17. F. Zhao, J. Yan, S. Deng et al., “A thioredoxin reductase inhibitor induces growth inhibition and apoptosis in five cultured human carcinoma cell lines,” Cancer Letters, vol. 236, no. 1, pp. 46–53, 2006. View at Publisher · View at Google Scholar · View at Scopus
18. D. Mustacich and G. Powis, “Thioredoxin reductase,” Biochemical Journal, vol. 346, no. 1, pp. 1–8, 2000. View at Publisher · View at Google Scholar · View at Scopus
19. K. Becker, C. Herold-Mende, J. J. Park, G. Lowe, and R. Heiner Schirmer, “Human thioredoxin reductase is efficiently inhibited by (2,2′:6′,2′-terpyridine)platinum(II) complexes. Possible implications for a novel antitumor strategy,” Journal of Medicinal Chemistry, vol. 44, no. 17, pp. 2784–2792, 2001. View at Publisher · View at Google Scholar · View at Scopus
20. L. Zhong and A. Holmgren, “Essential role of selenium in the catalytic activities of mammalian thioredoxin reductase revealed by characterization of recombinant enzymes with selenocysteine mutations,” Journal of Biological Chemistry, vol. 275, no. 24, pp. 18121–18128, 2000. View at Publisher · View at Google Scholar · View at Scopus
21. S. Gromer, J. Wissing, D. Behne et al., “A hypothesis on the catalytic mechanism of the selenoenzyme thioredoxin reductase,” Biochemical Journal, vol. 332, part 2, pp. 591–592, 1998. View at Google Scholar · View at Scopus
22. C. H. Williams Jr., L. David Arscott, S. Müller et al., “Thioredoxin reductase: two modes of catalysis have evolved,” European Journal of Biochemistry, vol. 267, no. 20, pp. 6110–6117, 2000. View at Publisher · View at Google Scholar · View at Scopus
23. P. M. Scarbrough, K. A. Mapuskar, D. M. Mattson, D. Gius, W. H. Watson, and D. R. Spitz, “Simultaneous inhibition of glutathione- and thioredoxin-dependent metabolism is necessary to potentiate 17AAG-induced cancer cell killing via oxidative stress,” Free Radical Biology and Medicine, vol. 52, no. 2, pp. 436–443, 2012. View at Publisher · View at Google Scholar · View at Scopus
24. C. D. Putnam, A. S. Arvai, Y. Bourne, and J. A. Tainer, “Active and inhibited human catalase structures: ligand and NADPH binding and catalytic mechanism,” Journal of Molecular Biology, vol. 296, no. 1, pp. 295–309, 2000. View at Publisher · View at Google Scholar · View at Scopus
25. T. Keleş, “Synthesis of new water soluble aminomethylphosphine and their metal complexes and investigation of their biological activity,” Department of Chemistry Institue of Natural and Applied Sciences University of Çukurova, ADANA, 2013.
26. B. Akkuş, Synthesis of Transitıon Metal Complexes with Mixed Ligands and Characterization, Department of Chemistry, Institue of Natural and Applied Sciences, University of Çukurova, Adana, Turkey, 2009.
27. S. Tardito, C. Isella, E. Medico et al., “The thioxotriazole copper (II) complex A0 induces endoplasmic reticulum stress and paraptotic death in human cancer cells,” Journal of Biological Chemistry, vol. 284, no. 36, pp. 24306–24319, 2009. View at Publisher · View at Google Scholar · View at Scopus
28. A. Claiborne, “Catalase activity,” in Handbook of Methods for Oxygen Radical Research, R. A. Greenwald, Ed., pp. 283–284, CRC Press, Boca Raton, Fla, USA, 1985. View at Google Scholar
29. O. H. Lowry, N. J. Rosebrough, A. L. Farr, and R. J. Rondall, “Protein measurement with the Folin phenol reagent,” The Journal of Biological Chemistry, vol. 193, no. 1, pp. 265–275, 1951. View at Google Scholar · View at Scopus
30. E. Beutler and E. Beutler, “Red cell metabolism,” in A Manual of Biochemical Methods, pp. 66–68, Grone & Stratton, New York, NY, USA, 1971. View at Google Scholar
31. S. Gromer, L. D. Arscott, C. H. Williams Jr., R. H. Schirmeri, and K. Becker, “Human placenta thioredoxin reductase. Isolation of the selenoenzyme, steady state kinetics, and inhibition by therapeutic gold compounds,” The Journal of Biological Chemistry, vol. 273, no. 32, pp. 20096–20101, 1998. View at Publisher · View at Google Scholar · View at Scopus
32. D. G. Kleinbaum, L. L. Kupper, K. E. Muller, and A. Nizan, Applied Regression Analysis and Other Multivariate Methods, Duxbury Press, Boston, Mass, USA, 1998.
33. P. E. Garrou, “Δ_R ring contributions to 31P NMR parameters of transition-metal-phosphorus chelate complexes,” Chemical Reviews, vol. 81, no. 3, pp. 229–266, 1981. View at Publisher · View at Google Scholar · View at Scopus
34. F. R. Pavan, G. V. Poelhsitz, M. I. F. Barbosa et al., “Ruthenium(II) phosphine/diimine/picolinate complexes: inorganic compounds as agents against tuberculosis,” European Journal of Medicinal Chemistry, vol. 46, no. 10, pp. 5099–5107, 2011. View at Publisher · View at Google Scholar · View at Scopus
35. G. Lupidi, L. Avenali, M. Bramucci et al., “Synthesis, properties, and antitumor effects of a new mixed phosphine gold(I) compound in human colon cancer cells,” Journal of Inorganic Biochemistry, vol. 124, pp. 78–87, 2013. View at Publisher · View at Google Scholar · View at Scopus
36. P. Mura, M. Camalli, A. Bindoli et al., “Activity of rat cytosolic thioredoxin reductase is strongly decreased by trans-[bis(2-amino-5-methylthiazole)tetrachlororuthenate(III)]: first report of relevant thioredoxin reductase inhibition for a ruthenium compound,” Journal of Medicinal Chemistry, vol. 50, no. 24, pp. 5871–5874, 2007. View at Publisher · View at Google Scholar · View at Scopus
37. A.-B. Witte, K. Anestål, E. Jerremalm, H. Ehrsson, and E. S. J. Arnér, “Inhibition of thioredoxin reductase but not of glutathione reductase by the major classes of alkylating and platinum-containing anticancer compounds,” Free Radical Biology & Medicine, vol. 39, no. 5, pp. 696–703, 2005. View at Publisher · View at Google Scholar · View at Scopus
38. A. K. Renfrew, A. E. Egger, R. Scopelliti, C. G. Hartınger, and P. J. Dyson, “Synthesis and characterisation of the water soluble bis -phosphine complex [Ru(${\eta }^6$-cymene)(PPh₂ (o-C₆H₄O)-$k^2-P,O$)(pta)]⁺ and an investigation of its cytotoxic effects,” Comptes Rendus Chimie, vol. 13, no. 8-9, pp. 1144–1150, 2010. View at Publisher · View at Google Scholar
39. P. C. A. Bruijnincx and P. J. Sadler, “New trends for metal complexes with anticancer activity,” Current Opinion in Chemical Biology, vol. 12, no. 2, pp. 197–206, 2008. View at Publisher · View at Google Scholar · View at Scopus
40. S. M. Guichard, R. Else, E. Reid et al., “Anti-tumour activity in non-small cell lung cancer models and toxicity profiles for novel ruthenium(II) based organo-metallic compounds,” Biochemical Pharmacology, vol. 71, no. 4, pp. 408–415, 2006. View at Publisher · View at Google Scholar · View at Scopus
41. S. Gromer, L. D. Arscott, C. H. Williams Jr., R. H. Schirmeri, and K. Becker, “Human placenta thioredoxin reductase,” The Journal of Biological Chemistry, vol. 273, no. 32, pp. 20096–20101, 1998. View at Publisher · View at Google Scholar · View at Scopus
42. E. Vergara, A. Casini, F. Sorrentino et al., “Anticancer therapeutics that target selenoenzymes: synthesis, characterization, in vitro cytotoxicity, and thioredoxin reductase inhibition of a series of gold(I) complexes containing hydrophilic phosphine ligands,” ChemMedChem, vol. 5, no. 1, pp. 96–102, 2010. View at Publisher · View at Google Scholar · View at Scopus
43. K. Becker, S. Gromer, R. H. Schirmer, and S. Müller, “Thioredoxin reductase as a pathophysiological factor and drug target,” European Journal of Biochemistry, vol. 267, no. 20, pp. 6118–6125, 2000. View at Publisher · View at Google Scholar · View at Scopus
44. Y. Nishinaka, H. Nakamura, H. Masutani, and J. Yodoi, “Redox control of cellular function by thioredoxin; a new therapeutic direction in host defence,” Archivum Immunologiae et Therapiae Experimentalis, vol. 49, no. 4, pp. 285–292, 2001. View at Google Scholar · View at Scopus
45. J. Nordberg and E. S. J. Arnér, “Reactive oxygen species, antioxidants, and the mammalian thioredoxin system,” Free Radical Biology & Medicine, vol. 31, no. 11, pp. 1287–1312, 2001. View at Publisher · View at Google Scholar · View at Scopus
46. R. G. Pearson, “Acids and bases,” Science, vol. 151, no. 3707, pp. 172–177, 1966. View at Publisher · View at Google Scholar · View at Scopus
47. A. Cingolani, J. V. Hanna, M. Pellei et al., “Crystal structures and vibrational and solution and solid-state (CPMAS) NMR spectroscopic studies in triphenyl phosphine, arsine, and stibine silver(I) bromate systems, (R₃E)xAgBrO₃ (E = P, As, Sb; $x=1-4$),” Inorganic Chemistry, vol. 42, no. 16, pp. 4938–4948, 2003. View at Publisher · View at Google Scholar · View at Scopus
48. K. G. Daniel, P. Gupta, R. H. Harbach, W. C. Guida, and Q. P. Dou, “Organic copper complexes as a new class of proteasome inhibitors and apoptosis inducers in human cancer cells,” Biochemical Pharmacology, vol. 67, no. 6, pp. 1139–1151, 2004. View at Publisher · View at Google Scholar · View at Scopus
49. C. Marzano, V. Gandin, A. Folda, G. Scutari, A. Bindoli, and M. P. Rigobello, “Inhibition of thioredoxin reductase by auranofin induces apoptosis in cisplatin-resistant human ovarian cancer cells,” Free Radical Biology & Medicine, vol. 42, no. 6, pp. 872–881, 2007. View at Publisher · View at Google Scholar · View at Scopus
50. J. L. Hirpara, M.-V. Clément, and S. Pervaiz, “Intracellular acidification triggered by mitochondrial-derived hydrogen peroxide is an effector mechanism for drug-induced apoptosis in tumor cells,” Journal of Biological Chemistry, vol. 276, no. 1, pp. 514–521, 2001. View at Publisher · View at Google Scholar · View at Scopus
51. Q. Chen, M. G. Espey, M. C. Krishna et al., “Pharamacologic ascorbic acid concentrations selectively kill cancer cells: action as a pro-drug to deliver hydrogen peroxide to tissuse,” Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 38, pp. 13604–13609, 2005. View at Publisher · View at Google Scholar · View at Scopus
52. A. M. Evens, P. Lecane, D. Magda et al., “Motexafin gadolinium generates reactive oxygen species and induces apoptosis in sensitive and highly resistant multiple myeloma cells,” Blood, vol. 105, no. 3, pp. 1265–1273, 2005. View at Publisher · View at Google Scholar · View at Scopus
53. M. López-Lázaro, “Dual role of hydrogen peroxide in cancer: possible relevance to cancer chemoprevention and therapy,” Cancer Letters, vol. 252, no. 1, pp. 1–8, 2007. View at Publisher · View at Google Scholar · View at Scopus